• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Differences in cancer implications for clinical care among CHEK2 variants

byDaniel GoldshteinandSze Wah Samuel Chan
December 28, 2022
in Genetics, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Some CHEK2 alleles were shown to have a high-risk association of breast cancer compared to other alleles that were deemed low-risk or compared to wild-type CHEK2

2. CHEK2 pathological variants were shown to be statistically associated with other cancers such as kidney and thyroid

Evidence Rating Level: 2 (Good)

Study Rundown: The CHEK2 gene and its associated product, CHK2 protein kinase, has been found to be a tumor suppressor through its activity in DNA damage repair. Certain pathologic variants (PVs) of CHEK2, such as variant c.1100del which is a loss-of-function variant have been shown to be associated with breast cancer, whereas missense variants like p.I157T, p.S428F, and p.T476M have had mixed association with breast cancer. This current study looked at patients with CHEK2 PVs and compared them with those that had wild-type CHEK2. They found that CHEK2 PVs were mostly associated with women of Caucasian descent, of which a large percentage were found to have breast cancer. Certain PV such as c.444+1G>A, ex8_9del, p.R117G, and c.1100del were shown to have a high-risk association of breast cancer compared to other alleles (p.I157T, p.S428F, and p.T476M) that were deemed low-risk or compared to wild-type CHEK2. Other cancers were also implicated in their association with CHEK2 PVs. The median age of diagnosis in certain cancers were also younger in those with certain PVs compared to wild-type or other PVs. Strengths of this study included the robust genetic testing available at this single center, and the large sample size. Limitations to this study included a population that was lacking diversity, as well as its observational nature. Overall, furthering our understanding of CHEK2 PVs can help guide clinical and genetic risk assessments for patients affected by those mutations.

Click to read the study in JAMA Oncology

Relevant Reading: Structure and Activation Mechanism of the CHK2 DNA Damage Checkpoint Kinase

In-Depth [retrospective cohort]: This study compared patients with CHEK2 PVs (3,783) found on genetic testing at a single laboratory between 2012 to 2019, against patients with CHEK2 wild-type (n = 33,034) and investigated further associations with cancer panel testing. In general, 74.5% of individuals with CHEK2 PVs had cancer. 91.8% of individuals were female, out of which 63.4% of females had breast cancer. Breast cancer was most prevalent in the following PVs compared to wild-type; c.444+1G>A (OR 2.63, 95% 1.59-4.35), ex8_9del (OR 2.36, 95% 1.53-3.64), p.R117G (OR 1.65, 95% 1.12-2.44) and c.1100del (OR 1.76, 95% 1.55-2.00). CHEK2 PVs, especially the c.1100del PV, were also associated with kidney cancer (OR 2.57, 95%CI 1.75-3.68) and thyroid cancer (OR 1.63, 95%CI 1.26-2.08) compared with wild-type. It was also found that biallelic CHEK2 PV had a younger age of any cancer diagnosis (median 37 vs 47 years of age, p<0.001) compared to monoallelic PV. While the following CHEK2 PV did not have any significant difference in frequencies of any cancer compared to wild-type, they were associated with decreased levels of cancer when compared to other PVs; p.I157T (OR 0.66, 95%CI 0.56-0.78) and p.S428F (OR 0.5, 95%CI 0.39-0.65), with p.T467 showing non-significant decrease. Overall, the findings of this paper suggest that future genetic and clinical counselling may be informative for patients who are found to have CHEK2 PVs.

RELATED REPORTS

Combination therapy with alisterib and fulvestrant may be clinically advantageous in the treatment of endocrine-resistant advanced breast cancer

Liver enzymes elevated at 6 months prior to breast cancer liver metastasis detection

#StudyGraphics: Adjuvant abemaciclib improves survival in patients with hormone receptor-positive early breast cancer

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Breast CancerCHEK2genetics
Previous Post

Inappropriate clinical management decisions are possible secondary to use of Bazett formula for QTc in context of chemotherapy cancer treatment

Next Post

Bionic pancreas reduces glycated hemoglobin levels compared to semi-automated insulin-delivery systems

RelatedReports

Preoperative bilateral breast imaging may reduce contralateral cancer recurrence
Chronic Disease

Combination therapy with alisterib and fulvestrant may be clinically advantageous in the treatment of endocrine-resistant advanced breast cancer

March 12, 2023
Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ
Gastroenterology

Liver enzymes elevated at 6 months prior to breast cancer liver metastasis detection

March 8, 2023
#StudyGraphics: Adjuvant abemaciclib improves survival in patients  with hormone receptor-positive early breast cancer
StudyGraphics

#StudyGraphics: Adjuvant abemaciclib improves survival in patients with hormone receptor-positive early breast cancer

March 8, 2023
Adjunctive TMP-SMX (Bactrim) associated with higher clinical cure rates for cutaneous abscesses
Obstetrics

Low household income associated with worse outcomes for estrogen receptor-positive breast cancer

February 28, 2023
Next Post
Rectal indomethacin dose escalation for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography in high-risk patients

Bionic pancreas reduces glycated hemoglobin levels compared to semi-automated insulin-delivery systems

Remote patient monitoring did not reduce heart failure readmissions: The BEAT-HF trial

Acetazolamide increases rate of successful decongestion in patients with acute decompensated heart failure

Patient-reported outcome measures in cardiovascular disease have limited validation of psychometric properties

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Specific histopathologic renal lesions may be associated with increased risk of cardiovascular disease
  • Symptom and viral relapse more common in COVID-19 patients without antiviral treatment
  • The Scan by 2 Minute Medicine®: Endometriosis Awareness Month, OnlineMedEd Charges, Canadian Grocery Store Controversy, BetterHelp’s Privacy Concerns
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options